Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Inclusion Criteria: * Have a diagnosis of cancer with no previous chemotherapy treatments (aside from current treatment) * Be scheduled to receive treatment with a chemotherapeutic agent that is classified by the National Comprehensive Cancer Network (NCCN) as having a high emetogenic potential (\>90% incidence) or moderate emetogenic potential (30-90% incidence). * Must be scheduled for a minimum of 3 additional chemotherapy cycles at the time of enrollment. * Chemotherapy agents may be given intravenously or orally. * Chemotherapy cycles must be at least two weeks apart. * For the purposes of this study, Day 1 is defined as the day of chemotherapy administration. * Chemotherapy may be for adjuvant, neoadjuvant, curative, or palliative intent. * Highly emetogenic - common types of chemotherapy * AC combination defined as any chemotherapy regimen that contains an anthracycline and cyclophosphamide * Carboplatin AUC ≥4 * Carmustine \>250 mg/m2 * Cisplatin * Cyclophosphamide \>1,500 mg/m2 * Dacarbazine * Doxorubicin ≥60 mg/m2 * Epirubicin \>90 mg/m2 * Ifosfamide ≥2 g/m2 per dose * Mechlorethamine * Streptozocin * Moderately emetogenic - common types of chemotherapy: * Aldesleukin \>12-15 million IU/m2 * Amifostine \>300 mg/m2 * Arsenic trioxide * Azacitidine * Bendamustine * Busulfan * Carboplatin AUC \<4 * Carmustined ≤250 mg/m2 * Clofarabine * Cyclophosphamide ≤1500 mg/m2 * Cytarabine \>200 mg/m2 * Dactinomycin * Daunorubicin…